Le Lézard
Classified in: Health
Subject: SVY

United States Acne and Rosacea Industry Insights 2020-2024 - Leading Players are Allergan, Bausch Health Companies, Leo Pharma, Sol Gel Technologies, Foamix Pharmaceuticals and Galderma


DUBLIN, Aug. 7, 2020 /PRNewswire/ -- The "US Acne & Rosacea Market: Insights, Trends & Forecast (2020-2024)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The US acne market is expected to reach US$4.49 billion in 2024, recording growth at a CAGR of 4.12% during the period spanning 2019-2024. The US rosacea market is expected to reach US$1.8 billion in 2024, growing at a CAGR of 5.92% during the period spanning 2019-2024.

Growth in the acne and rosacea market has accrued due to the rising youth population, the increasing purchasing power of consumers and escalating healthcare expenditure. The market is anticipated to experience certain trends like growing awareness about acne & rosacea and their treatments and the increasing importance of personal appearance. The US acne & rosacea market would face challenges regarding entry of generic drugs and side effects of therapies.

Scope of the Report

Market Segmentation and Insights

Key Topics Covered

1. Market Overview
1.1 Acne
1.1.1 Acne Overview
1.1.2 Causes & Symptoms of Acne
1.1.3 Classification of Severity
1.1.4 Treatment for Acne
1.1.5 Acne Treatment Continuum
1.1.6 Limitations of Acne Treatments
1.2 Rosacea
1.2.1 Rosacea Overview
1.2.2 Symptoms and Causes of Rosacea
1.2.3 Treatment for Rosacea

2. The US Acne Market
2.1 The US Acne Market Forecast by Value
2.2 The US Acne Market by Drug Type
2.3 The US Acne Topical Drugs by Brand
2.4 The US Acne Oral Antibiotics by Brand
2.5 The US Acne Market Forecast by Product
2.5.1 The US Minocycline Revenue Forecast
2.5.2 The US Retin-A Generics Revenue Forecast
2.5.3 The US Epiduo/Epiduo Forte Revenue Forecast
2.5.4 The US Aczone Revenue Forecast
2.5.5 The US Onexton Revenue Forecast
2.5.6 The US Solodyne Revenue Forecast
2.5.7 The US Oracea Revenue Forecast
2.5.8 The US Ziana Revenue Forecast
2.6 The US Acne Prevalence Forecast
2.7 The US Acne Addressable Population
2.7.1 The US Acne Addressable Population Forecast
2.7.2 The US Acne Addressable Population by Severity
2.7.3 The US Moderate Acne Population Forecast
2.7.4 The US Mild Acne Population Forecast
2.7.5 The US Severe Acne Population Forecast
2.8 The US Acne Topical Treatment Population
2.8.1 The US Acne Topical Treatment Population Forecast
2.8.2 The US Acne Topical Treatment Population by Severity
2.8.3 The US Acne Topical Treatment Moderate Population Forecast
2.8.4 The US Acne Topical Treatment Moderate Population Forecast
2.8.5 The US Severe Acne Topical Treatment Population Forecast
2.9 FMX101
2.9.1 The US FMX-101 Drug Market Share Forecast
2.9.2 The US FMX-101 Drug Cost Forecast
2.9.3 The US FMX-101 Drug Revenue Forecast
2.10 TWIN
2.10.1 The US TWIN Drug Patient Population Forecast
2.10.2 The US TWIN Drug Market Share Forecast
2.10.3 The US TWIN Drug Cost Forecast
2.10.4 The US TWIN Drug Revenue Forecast
2.11 SIRS-T
2.11.1 The US SIRS-T Drug Patient Population Forecast
2.11.2 The US SIRS-T Drug Market Share Forecast
2.11.3 The US SIRS-T Drug Cost Forecast
2.11.4 The US SIRS-T Drug Revenue Forecast

3. The US Rosacea Market
3.1 The US Rosacea Market Forecast by Value
3.2 The US Rosacea Total Cases Forecast
3.3 The US Rosacea Market by Drug Type
3.3.1 The US Rosacea Market Revenue and Prescription by Brand
3.4 The US Rosacea Prevalence Forecast
3.5 The US Rosacea Addressable Population
3.5.1 The US Rosacea Addressable Population Forecast
3.5.2 The US Rosacea Addressable Population by Severity
3.5.3 The US Mild Rosacea Population Forecast
3.5.4 The US Moderate Rosacea Population Forecast
3.5.5 The US Severe Rosacea Population Forecast
3.6 The US Rosacea Topical Treatment Population
3.6.1 The US Rosacea Topical Treatment Population Forecast
3.6.2 The US Rosacea Topical Treatment Population by Severity
3.6.3 The US Moderate Rosacea Topical Treatment Population Forecast
3.6.4 The US Mild Rosacea Topical Treatment Population Forecast
3.6.5 The US Severe Rosacea Topical Treatment Population Forecast
3.7 FMX103
3.7.1 The US FMX-103 Drug Market Share Forecast
3.7.2 The US FMX-103 Drug Revenue Forecast
3.8 VERED
3.8.1 The US VERED Drug Patient Population Forecast
3.8.2 The US VERED Drug Market Share Forecast
3.8.3 The US VERED Drug Cost Forecast
3.8.4 The US VERED Drug Revenue Forecast

4. Market Dynamics
4.1 Growth Drivers
4.1.1 Increasing Youth Population
4.1.2 Rising Purchasing Power
4.1.3 Escalating Healthcare Expenditure
4.1.4 Vast Market Opportunity
4.1.5 Sedentary Lifestyle and Unhealthy Eating Habits
4.2 Key Trends & Developments
4.2.1 Growing Awareness
4.2.2 Increasing Medical Tourism
4.2.3 Preference for Minimally Invasive Procedures
4.2.4 Importance of Personal Appearance
4.3 Challenges
4.3.1 Entry of Generic Drugs
4.3.2 Side Effects of Acne and Rosacea Therapies
4.3.3 Tough Regulations

5. Competitive Landscape
5.1 Global Market
5.1.1 Revenue Comparison - Key Players
5.1.2 Market Capitalization Comparison - Key Players
5.1.3 Research & Development Comparison - Key Players
5.1.4 Global Acne Market- Drug Comparison by Company
5.1.5 Global Late Stage Acne Market- Drug Comparison by Company
5.1.6 Global Mid Stage Acne Market- Drug Comparison by Company
5.1.7 Global Rosacea Market- Drug Comparison by Company

6. Company Profiles
6.1 Bausch Health Companies, Inc.
6.1.1 Business Overview
6.1.2 Financial Overview
6.1.3 Business Strategies
6.2 Foamix Pharmaceuticals Ltd.
6.3 Allergan PLC
6.4 Sol Gel Technologies Ltd.
6.5 Galderma
6.6 Leo Pharma

For more information about this report visit https://www.researchandmarkets.com/r/5kf6le

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 10:00
Acara Partners founder and CEO, Francis X. Acunzo, had the privilege of presenting two virtual webinars on the state of the industry at the Aesthetic Next Conference which ran over the weekend of September 11. Aesthetic Next was hosted by Aesthetic...

25 sep 2020
Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC ("KSF"), announces that KSF has commenced an investigation into Vaxart, Inc. . In early 2020, the Company, which focuses on...

25 sep 2020
Montage Resources Corporation WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Montage Resources Corporation in connection with the proposed acquisition of the company by...

25 sep 2020
The National Society of College Scholars (NSCS) is proud to announce a new community service partnership with The Alzheimer's Association. NSCS members will participate in a community service project through The Alzheimer's Association's Longest Day®...

25 sep 2020
Pomerantz LLP announces that a class action lawsuit has been filed against BioMarin Pharmaceuticals, Inc.  ("BioMarin" or the "Company") and certain of its officers.   The class action, filed in United States District Court for the Northern District...

25 sep 2020
Century Specialty Script, LLC ("Century"), a specialty pharmacy which provides an array of specific and personalized services in all pharmacy related matters, announced today that it has taken action after learning of a data security incident which...



News published on 7 august 2020 at 19:00 and distributed by: